Pigpen is a cellular binding protein of therapeutic oligonucleotides

Cytotherapy

Volumn 7, Issue 2, 2005, Pages 186-194

  Zhang, Zhiren ^a   Schluesener, H J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Binding proteins; Cellular localization; Oligonucleotides; Pigpen

Indexed keywords

BINDING PROTEIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PIGPEN PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELL NUCLEUS; CELL NUCLEUS MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOPLASM; DRUG PROTEIN BINDING; DRUG UPTAKE; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MASS SPECTROMETRY; MICROGLIA; MOUSE; NONHUMAN; NUCLEOLUS; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; RAT;

EID: 21044457564     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240510027091     Document Type: Article

References (36)

1. Loke SL, Stein CA, Zhang XH et al. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 1989;86:3474-8.
2. Yakubov LA, Deeva EA, Zarytova VF et al. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc Natl Acad Sci USA 1989;86:6454-8.
3. Beltinger C, Saragovi HU, Smith RM et al. Binding, uptake and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 1995;95:1814-23.
4. Leonetti JP, Mechti N, Degols G et al. Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci USA 1991;88:2702-6.
5. Lorenz P, Misteli T, Baker BF et al. Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 2000;28:582-92.
6. Zhang Z, Weinschenk T, Schluesener HJ. Uptake, intracellular distribution, and novel binding proteins of immunostimulatory CpG oligodeoxynucleotides in microglial cells. J Neuroimmunol 2005;160:32-40.
7. Alliegro MC, Alliegro MA. A nuclear protein regulated during the transition from active to quiescent phenotype in cultured endothelial cells. Dev Biol 1996;174:288-97.
8. Alliegro MC, Alliegro MA. Identification of a new coiled body component. Exp Cell Res 1997;231:386-90.
9. Alliegro MC. Pigpen and endothelial cell differentiation. Cell Biol Int 2001;25:577-84.
10. Alappat SR, Zhang M, Zhao X et al. Mouse pigpen encodes a nuclear protein whose expression is developmentally regulated during craniofacial morphogenesis. Dev Dyn 2003;228:59-71.
11. Blank M, Weinschenk T, Priemer M, Schluesener H. Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. Selective targeting of endothelial regulatory protein pigpen. J Biol Chem 2001;276:16464-8.
12. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of protein silver-stained polyacrylamide gels. Anal Chem 1996;68:850-8.
13. Arnott D, O'Connell KL, King KL, Stults JT. An integrated approach to proteome analysis: identification of proteins associated with cardiac hypertrophy. Anal Biochem 1998;258:1-18.
14. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999;20:3551-67.
15. Luo C, Kallajoki M, Gross R et al. Cellular distribution and contribution of cyclooxygenase COX-2 to diabetogenesis in NOD mouse. Cell Tissue Res 2002;310:169-75.
16. Renshaw M, Rockwell J, Engleman C et al. Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol 2002;169:4697-701.
17. Dalpke AH, Schafer MK, Frey M et al. Immunostimulatory CpG-DNA activates murine microglia. J Immunol 2002;168: 4854-63.
18. Carpentier AF, Xie J, Mokhtari K, Delattre JY. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 2000;6:2469-73.
19. Baechtold H, Kuroda M, Sok J et al. Human 75-kDa DNA-pairing protein is identical to the pro-oncoprotein TLS/FUS and is able to promote D-loop formation. J Biol Chem 1999; 274:34337-42.
20. Clark RE. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaerma. Leuk Lymphoma 1995;19:189-95.
21. Juliano RL, Yoo H. Aspects of the transport and delivery of antisense oligonucleotides. Curr Opin Mol Ther 2000;2:297-303.
22. Islam A, Handley SL, Thompson KS, Akhtar S. Studies on uptake, sub-cellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems. J Drug Target 2000;7:373-82.
23. Benimetskaya L, Loike JD, Khaled Z et al. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nat Med 1997;3:414-20.
24. Biessen EA, Vietsch H, Kuiper J et al. Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. Mol Pharmacol 1998;53:262-9.
25. Hanss B, Leal-Pinto E, Bruggeman LA et al. Identification and characterization of a cell membrane nucleic acid channel. Proc Natl Acad Sci USA 1998;95:1921-6.
26. Crooke ST. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1999;1489:31-44.
27. Schmajuk G, Sierakowska H, Kole R. Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake. J Biol Chem 1999;274:21783-9.
28. Kukreti S, Sun JS, Garestier T, Helene C. Extension of the range of DNA sequences available for triple helix formation: stabilization of mismatched triplexes by acridine-containing oligonucleotides. Nucleic Acids Res 1997;25:4264-70.
29. Hu Q, Bally MB, Madden TD. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. Nucleic Acids Res 2002;30:3632-41.
30. de Diesbach P, N'Kuli F, Berens C et al. Receptor-mediated endocytosis of phosphodiester oligonuclecuides in the HepG2 cell line: evidence for non-conventional intracellular trafficking. Nucleic Acids Res 2002;30:1512-21.
31. Tonkinson JL, Stein CA. Patterns of intracellular compartmentalization, trafficking and acidification of 5′-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res 1994; 22:4268-75.
32. Pichon C, Arar K, Stewart AJ et al. Intracellular routing and inhibitory activity of oligonucleopeptides containing a KDEL motif. Mol Pharmacol 1997;51:431-8.
33. Leonetti JP, Mechti N, Degols G et al. Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci USA 1991;88:2702-6.
34. Clarenc JP, Lebleu B, Leonetti JP. Characterization of the nuclear binding sites of oligodeoxyribonucleotides and their analogs. J Biol Chem 1993;268:5600-4.
35. Lorenz P, Baker BF, Bennett CF, Spector DL. Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies. Mol Biol Cell 1998;9:1007-23.
36. Lorenz P, Misteli T, Baker BF et al. Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 2000;28:582-92.